Alfacell Selects TS Communications And Feinstein Kean Healthcare, Inc. For Comprehensive Integrated Communications

BLOOMFIELD, N.J.--(BUSINESS WIRE)--Sept. 18, 2006--Alfacell Corporation (Nasdaq: ACEL) today announced that it has engaged TS Communications Group (TSCG) and Feinstein Kean Healthcare (FKH) to integrate, enhance and accelerate the company's core investor relations and marketing communications efforts. The well-integrated, full-service TSCG/FKH team will focus on strategic and tactical support of ONCONASE(R) (ranpirnase), the company's lead drug candidate currently being evaluated in a Phase IIIb registration trial for the treatment of unresectable malignant mesothelimona (UMM) and a Phase I / II dose ranging study in non-small cell lung cancer in partnership with US Oncology. The company's portfolio of other novel ribonuclease (RNase)-derived therapeutics for cancer and other life-threatening diseases will also be supported.